Clinical Failure Analysis

{
  "failure_taxonomy": {
    "operational_failures": {
      "examples": [
        "COVID-19 disruption, enrollment failures in rare AD subpopulations"
      ],
      "pct": 4
    },
    "safety_termination": {
      "examples": [
        "ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"
      ],
      "key_trials": [
        "Aducanumab Phase 3 dose arm"
      ],
      "pct": 8
    },
    "wrong_endpoint": {
      "examples": [
        "ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"
      ],
      "key_trials": [
        "Multiple agents 2010-2020"
      ],
      "pct": 18
    },
    "wrong_patient_population": {
      "examples": [
        "Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"
      ],
      "key_trials": [
        "Bapineuzumab (mild-moderate vs. early)"
      ],
      "pct": 28
    },
    "wrong_target_or_hypothesis": {
      "examples": [
        "Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"
      ],
      "key_trials": [
        "Solanezumab",
        "Verubecestat",
        "Atabecestat"
      ],
      "pct": 42
    }
  },
  "historical_success_rates": {
    "overall_clinical_success_pct": 3.4,
    "phase2_to_phase3_pct": 31,
    "phase3_to_approval_pct": 11,
    "vs_all_diseases_benchmark": "Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)"
  },
  "lessons_learned": [
    "Early intervention is critical — treat pre-symptomatic or MCI only",
    "Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)",
    "CDR-SB global score now accepted primary endpoint by FDA (post-2018)",
    "ARIA management protocols must be pre-specified — not post-hoc",
    "Combination approaches (amyloid + tau + neuroinflammation) likely needed"
  ],
  "query_summary": {
    "condition": "Alzheimer Disease",
    "trials_analyzed": 78
  },
  "successful_design_principles": "CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration.",
  "what_still_might_fail": [
    "Tau-targeting agents if amyloid clearance alone sufficient",
    "Agents tested in wrong disease stage despite lessons",
    "CNS inflammation approaches without biomarker stratification"
  ]
}

# bash or zsh: see the payment challenge. Nothing is charged.
curl -sS -g -i 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis?condition=Disease+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Sepsis%22+%7C+%22ALS%22+%7C+%22Depression%22+%7C+%22NASH%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29'

# x402 v2 sends the challenge base64-encoded in the PAYMENT-REQUIRED header (v1 sends it in the body).
# To read the header:
curl -sS -g -o /dev/null -D - 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis?condition=Disease+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Sepsis%22+%7C+%22ALS%22+%7C+%22Depression%22+%7C+%22NASH%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29' \
  | grep -i '^payment-required:' | cut -d' ' -f2 | tr -d '\r' | base64 --decode

// npm i @x402/fetch @x402/evm viem
import { wrapFetchWithPayment, x402Client } from "@x402/fetch";
import { registerExactEvmScheme } from "@x402/evm/exact/client";
import { privateKeyToAccount } from "viem/accounts";

// Pays at most $0.2 per call.
const client = new x402Client().setSpendControls({ maxAmountPerPayment: "$0.2" });
registerExactEvmScheme(client, { signer: privateKeyToAccount(process.env.EVM_PRIVATE_KEY) });
const pay = wrapFetchWithPayment(fetch, client);

// Not sure it's safe to pay? ToolVet checks it first for $0.005. Pay for that from a separate
// client: this one is capped at $0.2 per payment. GET https://toolvet.app/api/v1/check?url=https%3A%2F%2Fclinicalintelpulse.theaslangroupllc.com%2Fapi%2Fclinical%2Ffailure-analysis
const res = await pay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis?condition=Disease+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Sepsis%22+%7C+%22ALS%22+%7C+%22Depression%22+%7C+%22NASH%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29");
console.log(res.status, await res.text());

# pip install "x402[requests,evm]"
import os
from eth_account import Account
from x402 import x402ClientSync
from x402.http.clients import x402_requests
from x402.mechanisms.evm import EthAccountSigner
from x402.mechanisms.evm.exact.register import register_exact_evm_client

# Pays at most $0.2 per call.
client = x402ClientSync().set_spend_controls({"max_amount_per_payment": "$0.2"})
register_exact_evm_client(client, EthAccountSigner(Account.from_key(os.environ["EVM_PRIVATE_KEY"])))

with x402_requests(client) as session:
    res = session.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis?condition=Disease+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Sepsis%22+%7C+%22ALS%22+%7C+%22Depression%22+%7C+%22NASH%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29")
    print(res.status_code, res.text)